ADT, androgen deprivation therapy; Brachytherapy; CSS, cancer specific survival; CT, computerized tomography; CTCAE, common terminology criteria for adverse events; CTV, clinical target volume; Cost-effectivness; D90, dose delivered to 90% of the clinical target volume; DFS, disease-free survival; DNR, dose non-homogeneity ratio; DVH, dose volume histogram; EBRT, external beam radiation therapy; EQD2, equivalent dose at 2 Gy per fraction; GI, gastro-intestinal; GTV1, initial gross volume tumor; GTV2, relapse gross volume tumor; GU, genito-urinary; HDB, high-dose rate brachytherapy; HR, high risk; High dose rate; IIEF, international index of erectile function; IPSS, International prostate symptom score; IR, intermediate risk; ISUP, International Society of Urological Pathology; ITPL, index tumor predominant lesion; LDR, low dose-rate; LIR, low-intermediate risk; LR, low risk; MFU, median follow up; NCCN, national comprehensive cancer network; OAR, organs at risks; OS, overall survival; PC, prostate cancer; PET, positron emission tomography; PSA, prostate specific antigen; PUF, peak urine flow; PVRV, post-void residual volume; Prostate cancer; QLQ-PR25, quality of life questionnaire for prostate cancer; QLQC30, quality of life questionnaire cancer patients; QoL, quality of life; SBRT, Stereotactic Body Radiation therapy; SDRT, Single Dose Radiotherapy; Single fraction; TURP, Transurethral resection of the prostate; V100, percentage of the clinical target volume receiving 100% of the prescribed dose; V110U, percentage of the urethra volume receiving 110% of the prescribed dose; V150, percentage of the clinical target volume receiving 150% of the prescribed dose; V200, percentage of the clinical target volume receiving 200% of the prescribed dose; V85R, percentage of the rectal volume receiving 85% of the prescribed dose; bRFS, biochemical relapse free survival; lRFS, local relapse free survival; mRFS, metastatic relapse-free survival; mpMRI, multi-parametric magnetic resonance imaging; pts, patients